Apixaban and Bradycardia - a phase IV clinical study of FDA data

Summary:

Bradycardia is reported as a side effect among people who take Apixaban (apixaban), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Amlodipine, and have Atrial fibrillation/flutter.

The phase IV clinical study analyzes which people have Bradycardia when taking Apixaban. It is created by eHealthMe based on reports of 60,044 people who have side effects when taking Apixaban from the FDA, and is updated regularly.

What is Apixaban?

Apixaban has active ingredients of apixaban. It is often used in blood clots. eHealthMe is studying from 60,351 Apixaban users. Check the latest studies of Apixaban.

What is Bradycardia?

Bradycardia (abnormally slow heart action) is found to be associated with 1,912 drugs and 3,118 conditions by eHealthMe. Check the latest studies of Bradycardia.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Jul, 06, 2026

60,044 people reported to have side effects when taking Apixaban.
Among them, 640 people (1.07%) have Bradycardia.

Among these 640 people:

* Approximation only. Some reports may have incomplete information.

Do you take Apixaban and have Bradycardia?

- Check whether Bradycardia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Apixaban:

Apixaban (60,351 reports)

Bradycardia treatments and more:

Bradycardia (61,180 reports)

How severe was Bradycardia and when was it recovered:

Bradycardia in Apixaban

Expand to all the drugs that have ingredients of apixaban:

Bradycardia and drugs with ingredients of apixaban (1,320 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Apixaban:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Bradycardia:

Bradycardia (1,912 drugs)

Browse all the conditions that are associated with Bradycardia:

Bradycardia (3,118 conditions)

Related publications that referenced our studies

Schlumbrecht MP, Hehr K, "Cisplatin-induced bradycardia and the importance of the QT interval", Journal of Oncology Pharmacy Practice, 2015 Jan .
Oflaz MB, Kucukdurmaz Z, Guven AS, Karapinar H, Kaya A, Sancakdar E, Deveci K, Gul I, Erdem A, Cevit O, Icagasioglu FD, "Bradycardia seen in children with Crimean-Congo hemorrhagic fever", Vector-Borne and Zoonotic Diseases, 2013 Nov .
Schlumbrecht MP, Hehr K, "Cisplatin-induced bradycardia and the importance of the QT interval", Journal of Oncology Pharmacy Practice, 2015 Jan .
Oflaz MB, Kucukdurmaz Z, Guven AS, Karapinar H, Kaya A, Sancakdar E, Deveci K, Gul I, Erdem A, Cevit O, Icagasioglu FD, "Bradycardia seen in children with Crimean-Congo hemorrhagic fever", Vector-Borne and Zoonotic Diseases, 2013 Nov .

How the study uses the data?

The study uses data from the FDA. It is based on apixaban (the active ingredients of Apixaban) and Apixaban (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.